Article
Genotype-Guided P2Y12 Inhibitor Monotherapy Within 7 Days of Percutaneous Coronary Intervention in High Bleeding Risk Patients: The CHAMP Trial - A Pilot Study and Safety Assessment.
Mayo Clinic proceedings - 1 Jan 2025
Ingraham Brenden S, Huxley Samuel B, Lane Conor M, Gulati Rajiv, Lewis Bradley R, Jaffe Allan S, Bell Malcolm R, Lerman Amir, Pereira Naveen L, Moyer Ann M, Baudhuin Linnea M, Rihal Charanjit S, Singh Mandeep
Abstract excerpt
OBJECTIVE: To test the feasibility and safety of genotype guidance in the selection of P2Y12 monotherapy within 1 week of percutaneous coronary interventions (PCIs) among patients with high bleeding risk (HBR). PATIENT AND METHODS: The study was a single-center, open-label, pilot trial. Patients (n=100) with HBR (as defined by an academic research consortium) after successful PCI received dual antiplatelet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.